FDA grants Priority Review to AstraZeneca's osimertinib for stage III EGFR-mutated NSCLC after chemoradiotherapy, based on phase 3 LAURA trial results.
The FDA granted Priority Review to AstraZeneca's osimertinib (Tagrisso) for adult patients with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC) after chemoradiotherapy. The decision is based on the phase 3 LAURA trial, which showed a significant improvement in progression-free survival (PFS) compared to placebo. If approved, osimertinib could become a new standard of care for this patient population.
June 10, 2024
5 Articles